Startups
Shares of Arsanis, Inc. stock are up more than 25 percent in premarket trading after the company announced that it will merge with privately-held X4 Pharmaceuticals, Inc. as part of a reverse merger that will provide X4 with a quick path to being traded on the Nasdaq.
Roivant Sciences teamed with Cincinnati Children’s Hospital Medical Center to launch Aruvant Sciences. Roivant is the umbrella company run by Vivek Ramaswamy, which has launched a number of companies with “vant” in the names.
Germany’s pharma giant Merck KGaA, Darmstadt, Germany and Silicon Valley data analytics company Palantir Technologies are forming a joint venture called Syntropy. Syntropy will be based in Boston and will focus on cancer data analytics tools.
50/50 joint venture with investor syndicate led by Vivo Capital
In announcing the round, Camel-IDS said the finances will be used for a phase Ib/II trial of its lead program CAM-H2, a treatment option in HER2-positive cancers, while further developing preclinical programs and broadening the pipeline.
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
Gail Maderis, currently president and chief executive officer of South San Francisco-based Antiva Biosciences, has a rock-solid resume.
Cabaletta Bio launched out of the University of Pennsylvania with an exclusive license deal and two multi-year sponsored research agreements. The fledgling biotech company will work on engineered T cell products for B cell-mediated autoimmune disease.
One of the biggest areas of research when it comes to cancer is prediction, because the sooner cancer is detected, the higher the chance that the patient will survive. In most cases, cancer is diagnosed after it has already entered into the advanced stages, which severely decreases the effectiveness of current cancer treatments.
Three Boston-area developers, King Street Properties, Mugar Enterprises and the DiStefano family, have proposed a possible new life sciences campus in the area to compete with Kendall Square. It is a 607,900-square-foot campus on a 4.3-acre site in Allston, an officially recognized neighborhood of Boston.
PRESS RELEASES